Prostate adenocarcinoma transition to neuroendocrine small cell tumors requires ASCL1
RNA-seq (gene expression) · mouse · 12 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Mus musculus (mouse)
- Samples
- 12 samples: 12 samples, each with a distinct title — no replicated groupsGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Neuroendocrine Differentiation in Prostate Cancer Requires ASCL1Cancer research · 2024
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE264598_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1103220 and SRA study SRP503414. Searching any of these in the dataset finder brings you back here.
Any grouping that defines a comparison lives in the sample characteristics, which GEO records separately from the titles.
How we read this: Read from 12 sample titles: 12 distinct titles with little repetition. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8223564 RPM replicate 1, snRNAseq
- GSM8223565 RPM replicate 2, snRNAseq
- GSM8223566 RPM replicate 3, snRNAseq
- GSM8223567 RPMA replicate 1, snRNAseq
- GSM8223568 RPMA replicate 2, snRNAseq
- GSM8223569 RPMA replicate 3, snRNAseq
- GSM8223570 RPM in vitro replicate 2 (bulk RNAseq)
- GSM8223571 RPM in vitro replicate 3 (bulk RNAseq)
- GSM8223572 RPM in vitro replicate 4 (bulk RNAseq)
- GSM8223573 RPM in vitro replicate 5 (bulk RNAseq)
- GSM8223574 RPMA in vitro replicate 1 (bulk RNAseq)
- GSM8223575 RPMA in vitro replicate 2 (bulk RNAseq)
- GSE297143 EZH2 alters aggressive variant prostate cancer subtype evolution, but is not required for neuroendocrine prostate cancer [RNAseq] 54 samples shares neuroendocrine, prostate
- GSE271053 A forward genetic screen identifies Sirtuin1 as a driver of neuroendocrine prostate cancer [RNA-Seq] 43 samples shares neuroendocrine, prostate
- GSE296986 EZH2 alters aggressive variant prostate cancer subtype evolution, but is not required for neuroendocrine prostate cancer. [scRNA-seq] 17 samples shares neuroendocrine, prostate
- GSE235036 Notch signaling suppresses neuroendocrine differentiation and alters the tumor immune microenvironment in advanced prostate cancer 13 samples shares neuroendocrine, prostate
- GSE271066 A forward genetic screen identifies Sirtuin1 as a driver of neuroendocrine prostate cancer. 44 samples shares neuroendocrine, prostate
- GSE297048 EZH2 alters aggressive variant prostate cancer subtype evolution, but is not required for neuroendocrine prostate cancer [ChIP-seq] 40 samples shares neuroendocrine, prostate
- GSE262879 Single-cell RNA-sequencing of murine pancreatic tumors derived from the orthotopic transplantation of Smad4 wild-type (WT) or Smad4 knockout (KO) pancreatic ductal adenocarcinoma (PDAC) KPC organoids in nu/nu mice. 18 samples shares adenocarcinoma
- GSE236258 Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation 15 samples shares adenocarcinoma
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.